Lupin scales record high on hopes of hike in foreign investment limit

Image
Capital Market
Last Updated : Nov 24 2014 | 12:47 PM IST

Lupin rose 1.22% to Rs 1,482 at 12:01 IST on BSE on reports a government panel has cleared the company's request to raise foreign investment limit in the firm.

Meanwhile, the BSE Sensex was up 96.72 points, or 0.34%, to 28,431.35

On BSE, so far 54,453 shares were traded in the counter, compared with an average volume of 62,291 shares in the past one quarter.

The stock was volatile. The stock hit a record high of Rs 1,500 in intraday trade today, 24 November 2014. The stock hit a low of Rs 1,460.10 so far during the day. The stock hit a 52-week low of Rs 841.10 on 21 November 2013.

The stock had outperformed the market over the past one month till 21 November 2014, rising 7.04% compared with the Sensex's 6.62% rise. The scrip also outperformed the market in past one quarter, gaining 18.26% as against Sensex's 7.49% rise.

The large-cap company has an equity capital of Rs 89.82 crore. Face value per share is Rs 2.

Reports indicated that Lupin was looking to increase the foreign investment limit in the firm to 49%. Foreign institutional investors owned 31.75% stake in the firm as at 30 September 2014.

On a consolidated basis, Lupin's net profit rose 55.1% to Rs 630.04 crore on 19.4% rise in total income to Rs 3283.64 crore in Q2 September 2014 over Q2 September 2013.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB and cephalosporin segment. Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the third largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 24 2014 | 12:01 PM IST

Next Story